Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's What Investors Should Know About AstraZeneca's COVID Vaccine Data

TheMotleyFool

0 0

Here's What Investors Should Know About AstraZeneca's COVID Vaccine Data

AstraZeneca (NASDAQ: AZN) published data from its phase 3 clinical trials in The Lancet, but the full data set didn't answer the most important question about why a half-dose followed by a full dose worked better than two full doses. In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the issue and potential reasons for the phenomenon. They also talk about why investors shouldn't be particularly worried about any delay the confusing data might create.

Source Fool.com

Like: 0

AZN

Share